News: Bayer AG (BAYRY.PK)

BAYRY.PK on OTC Markets Group

137.70USD
11 Jul 2014
Price Change (% chg)

$-0.09 (-0.07%)
Prev Close
$137.79
Open
$137.25
Day's High
$137.80
Day's Low
$136.88
Volume
22,360
Avg. Vol
62,026
52-wk High
$145.20
52-wk Low
$108.45

Search Stocks
Select another date:

Tue, Jul 8 2014

French lawmakers back Roche cancer drug as cheap eye treatment

* EU shift to Avastin a threat to Novartis, Bayer profits

China approves Bayer deal to buy Dihon, other deals

SHANGHAI, July 4 - The Chinese Ministry of Commerce's anti-monopoly bureau has approved German drugmaker Bayer AG's deal for traditional Chinese medicine (TCM) drugmaker Dihon Pharmaceutical Group Co, in a raft of deals approved on Friday.

UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands

* Coppertone, Dr. Scholl's draw interest after $14 bln deal

CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands

(Corrects fourth paragraph to read "portfolio acquired from Merck", not "portfolio acquired by Merck")

German manufacturing grows in June at weakest rate in eight months: PMI

BERLIN, - German manufacturing grew at the slowest rate in eight months in June, a survey showed on Tuesday, adding to signs that the expansion in Europe's largest economy lost momentum in the second quarter.

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

Bayer's Stivarga endorsed for gastrointestinal stromal tumors

FRANKFURT, June 27 - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator.

New Issue-Bayer prices a dual tranche deal

Underlying govt bond Over the 3.25 pct January 2020 DBR

Bayer bets on gene therapy with Dimension deal

FRANKFURT/LONDON - Bayer has struck an alliance with U.S. biotech firm Dimension Therapeutics to develop a gene therapy for the treatment of haemophilia A, marking renewed interest in an approach to tackle the cause of diseases at a cellular level.

UPDATE 1-Bayer bets on gene therapy with Dimension deal

* UniQure, Bluebird Bio also working on gene therapies (Adds detail, background)

Select another date:

Press Releases

Search Stocks